Miransertib
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
Conditions
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
Trial Timeline
May 16, 2017 → Apr 11, 2022
NCT ID
NCT03094832About Miransertib
Miransertib is a phase 1/2 stage product being developed by Merck for PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT03094832. Target conditions include PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome.
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04980872 | Phase 2 | Active |
| NCT03094832 | Phase 1/2 | Terminated |
Competing Products
6 competing products in PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Miransertib | Merck | Phase 2 | 39 |
| Alpelisib | Novartis | Phase 2 | 42 |
| Alpelisib | Novartis | Phase 2 | 39 |
| Alpelisib + Placebo | Novartis | Phase 2 | 39 |
| alpelisib | Novartis | Pre-clinical | 30 |
| RLY-2608 + Placebo | Relay Therapeutics | Phase 2 | 36 |